Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1398
Shown on this page
12
Current sort
Recently updated
Campus scope
UCSF, San Francisco, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCSF, San Francisco, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 937–948 of 1,398 matching trials with a site at UCSF, San Francisco, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

NCT03821246
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
Interventions
Atezolizumab, Tocilizumab, Etrumadenant
Drug
Lead sponsor
David Oh
Other
Eligibility
18 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
San Francisco, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 9:33 AM EDT
Recruiting Phase 1 Interventional

Imaging of Solid Tumors Using FAP-2286

NCT04621435
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumors, Adult, Metastatic Cancer
Interventions
Gallium-68 labelled (68Ga-) FAP-2286, Positron Emission Tomography (PET) imaging, Copper-64 labeled (64Cu-) FAP-2286
Drug · Procedure
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 9:33 AM EDT
Recruiting Phase 4 Interventional

Psoriatic Immune Response to Tildrakizumab

NCT05390515
Status at this site: Recruiting
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Tildrakizumab Prefilled Syringe
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 9:33 AM EDT
Active, not recruiting Phase 3 Interventional

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

NCT04468659
Site status not listed — check the official record
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Interventions
Lecanemab, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 9:33 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Healthy Family Project: Tobacco Use and Smoke Exposure in Asian American Communities

NCT07049757
Status at this site: Recruiting
View directory record Official record
Conditions
Tobacco-Related Carcinoma, Smoking Cessation
Interventions
Smoking cessation education, Survey Administration, Telephone-Based Intervention, Urine Specimen Collection, Silicone Wrist Band, Interview, Focus Group
Other · Behavioral · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 9:33 AM EDT
Active, not recruiting No phase listed Observational

Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer

NCT03737695
Site status not listed — check the official record
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Carcinoma, Peritoneal Effusion, Recurrent Breast Carcinoma
Interventions
Biospecimen Collection, Medical Chart Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 9:33 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multisite Implementation of COMPRENDO

NCT06055296
Status at this site: Recruiting
View directory record Official record
Conditions
Pediatric Cancer
Interventions
COMPRENDO Peer Navigation Intervention
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
4
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 31, 2026, 9:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

SPIROMICS Study of Early COPD Progression (SOURCE)

NCT05033990
Status at this site: Recruiting
View directory record Official record
Conditions
COPD, Early-Onset
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
30 Years to 55 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 31, 2026, 9:33 AM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
Site status not listed — check the official record
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 31, 2026, 9:33 AM EDT
Active, not recruiting No phase listed Observational

Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program

NCT04632953
Site status not listed — check the official record
View directory record Official record
Conditions
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Interventions
No Intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
13
States / cities
Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 31, 2026, 9:33 AM EDT
Recruiting Phase 1 Interventional

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

NCT06917079
Status at this site: Recruiting
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
Interventions
BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 31, 2026, 9:33 AM EDT
Recruiting Not applicable Interventional

Comparing Ultrasound-Guided Transgluteal Nerve Block to Standard Care

NCT07397117
Status at this site: Recruiting
View directory record Official record
Conditions
Sciatica Acute
Interventions
nerve block with ropivacaine, Standard medical treatment
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 31, 2026, 9:33 AM EDT

About this UCSF institution page

What this page lists
ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of California, San Francisco at any site, browse by condition, or browse by U.S. city.